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ABSTRACT
Introduction: Tumor necrosis factor (TNF)-a
inhibitors are widely used for the treatment of
inflammatory diseases. One of the side effects of
TNF-inhibitors is the development of a
psoriatiform eruption, also known as
paradoxical psoriasis. In this case report, we
describe a patient with this side effect after
treatment with adalimumab and etanercept.
Case Report: A 45-year-old female was treated
with adalimumab 40 mg once every 2 weeks for
pustulosis palmoplantaris and psoriatic
arthritis. After 2 injections, the patient
developed a psoriatiform eruption on her
body, which improved after discontinuation of
adalimumab but worsened after treatment with
etanercept 50 mg twice weekly. Eventually, the
patient was treated with topical corticosteroids
and ustekinumab 45 mg once every 3 months
with a complete remission of the psoriatiform
eruption.
Discussion: Several case reports and reviews
have been published in recent years which
describe patients with a psoriatiform eruption
after treatment with TNF-a inhibitors. The
pathogenesis that causes this psoriatic
eruption is unclear. In conclusion, we describe
a patient with a psoriatiform eruption after
treatment with adalimumab and etanercept.
This patient had to discontinue the treatment
and eventually had a complete response after
treatment with topical corticosteroids and
treatment with ustekinumab.
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INTRODUCTION
Tumor necrosis factor (TNF)-a inhibitors have
been of great benefit in the treatment of
inflammatory diseases, such as Crohn’s
disease, rheumatoid arthritis, ankylosing
spondylitis and psoriasis [1]. With the
increased use of TNF-a inhibitors, it is
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important to recognize and understand the
cutaneous adverse effects [2]. A number of case
reports and case series describe patients who
develop psoriasiform eruptions while on TNF-a
inhibitors. These eruptions can exist of plaque,
pustular or guttate psoriasis. Nail psoriasis has
also been seen, with characteristic features of
onycholysis, discoloration and pitting. All
TNF-a inhibitors including inflixmab,
adalimumab and etanercept can be responsible
for these reactions [1–4].
In this case report, we describe a patient with
pustulosis palmoplantaris, who had worsening
of her primary skin disease and developed a
generalized psoriasiform eruption after
treatment with adalimumab and etanercept.
CASE REPORT
A 45-year-old woman presented at the
outpatient clinic because of disabling skin
lesions. On examination, we found
erythematous and squamous papules and
plaques on her trunks, limbs, palms of her
hands, soles of her feet, scalp and dystrophic
nails of both hands and feet (Fig. 1). The lesions
had started 2 months earlier, after starting
treatment with adalimumab 40 mg once every
2 weeks. This patient was known from 7 years
before with pustulosis palmoplantaris and
psoriatic arthritis. Because of this arthritis, her
rheumatologist started treatment with
adalimumab. Previous treatments were
triamcinolone injections (ineffective),
leflunomide (Arava), methotrexate, acitretin,
prednisone (all four were stopped because of
side effects) and UVB phototherapy.
After the first injection of adalimumab, the
patient experienced a positive effect on her
pustulosis palmoplantaris, but after the second
injection the lesions became worse and an itchy
rash started on the rest of her body. She was
given topical therapy with potent corticosteroid
creams and the treatment with adalimumab was
stopped. Despite this, the lesions especially of
her hands and feet got worse, leading to
immobility, and the patient was therefore
admitted to our clinical dermatology ward.
Biopsies were taken from the palm of her
hand and from one of the lesions on her arm
(Fig. 2). The biopsies showed hyper- and
parakeratosis, subcorneal pustels with
neutrophilic granulocytes and spongiosis. A
perivascular inflammation with extravasation
Fig. 1 June 2013, skin lesions after treatment with
adalimumab
Fig. 2 Skin biopsy shows hyper- and parakeratosis, sub-
corneal pustels with neutrophilic granulocytes and spon-
giosis, a perivascular inﬂammation with extravasation of
neutrophilic granulocytes
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of neutrophilic granulocytes was found. A
diagnosis of pustulosis palmoplantaris with a
psoriatic eruption caused by adalimimab was
made.
Blood examination showed a slightly
elevated C-reactive protein level and
leucocytosis. Antibodies against adalimumab
could be detected (95 AE/ml). The
adalimumab levels were measured by means of
enzyme-linked immunosorbent assay,
performed at the Laboratory for Monoclonal
Therapeutics, Sanquin Diagnostic Services. The
adalimumab blood serum level was 0.1 lg/ml.
Treatment was switched to etanercept 50 mg
twice weekly in combination with systemic
erythromycin 500 mg 4 times daily (Figs. 3, 4).
After 2 months, this treatment also failed.
Methotrexate (which was given in
combination with the last therapy) had to be
stopped because of subjective side effects.
After discontinuing etanercept treatment
and starting treatment with clarithromycin
300 mg three times daily, her skin condition
was slowly getting better. The patient was
treated in our daycare center multiple days a
week with different topical therapies, UVB
photo-therapy and multiple antibiotics. The
pustulosis palmoplantaris and the psoriatic
eruption were slowly getting better. Because of
worsening of her psoriatic arthritis, treatment
with ustekinumab was started. Eventually, the
psoriatic eruption that was started after
treatment with adalimumab was gone and the
pustulosis palmoplantaris on hands and feet
improved.
Compliance with Ethics Guidelines
Informed consent was obtained from the
patient for being included in the study.
DISCUSSION
Anti-TNF-a therapies are widely used in the
treatment of inflammatory disorders, such as
Fig. 3 July 2013, after submission to our clinical ward and
treatment with topical corticosteroids and tetracyclins
Fig. 4 September 2013, after treatment with etanercept
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psoriasis, arthritis and inflammatory bowel
diseases. Side effects of these treatments have
been reported, including a de novo or
worsening of psoriatic eruption. This adverse
reaction is also known in the literature as
paradoxical psoriasis. Many case reports and
case series have been published to describe these
patients who use either infliximab, adalimumab
or etanercept, with an incidence of 1–5% [1–4].
In larger case studies, no predisposing factors
for paradoxal psoriasis have been described.
Only a minority of the patients treated with
anti-TNF-a agents had a history of psoriasis or a
family member with psoriasis.
In a systematic literature review from 1996 to
2009, 207 patients suffering from paradoxal
psoriasis were analyzed. Patients were treated
with anti-TNF-a agents for rheumatoid arthritis,
seronegative spondylarthropathy,
inflammatory bowel disease, psoriasis or
others. Patients were treated with either
infliximab (59%), etanercept (19%) or
adalimumab (22%). The majority of these
patients developed plaque-type (50%), pustular
(56%) or guttate psoriasis (12%). Most patients
(67%) were able to continue their anti-TNF-a
treatment, and 57% of them had a complete or
partial remission of the psoriatic eruption [3].
Another systematic review showed similar
results [5]. In patients whose treatment was
discontinued, 32% had a complete remission of
the psoriatic eruption. Patients who continued
their therapy showed a complete remission of
29%. Of the patients who switched to another
anti-TNF-a therapy, 24% showed a complete
remission [5]. Other studies showed no
beneficial effect after switching to another
anti-TNF-a therapy [2].
Biopsies taken from the psoriatic lesions
caused by anti-TNF-a therapies showed in
most cases a psoriatiform pattern, but a
lichenoid pattern, spongiosis, epidermal
edema and neutrophilic infiltration have also
been reported [6, 7]. The pathogenesis that
causes this psoriatic eruption is unclear. There
are some hypotheses that can explain the
eruption. MxA (myxoprotein A) is a protein
that is induced by interferon (IFN) alpha and
beta. Biopsies taken from the psoriatic eruption
in patients with TNF-a inhibitors show an
increase in this MxA protein in comparison
with healthy controls and patients with a
psoriasis vulgaris. Anti-TNF-a therapies
produce a decrease of TNF-a, but can also
induce high levels of IFN, which may lead to
an increase of MxA protein [6].
IFN-a can also induce an increase of specific
receptors, including the chemokine receptor
CXCR3. This may lead to an increase of T-cells
and neutrophils in the skin, thus mimicking
psoriasis. Pro-inflammatory cytokines, induced
by IFN-a, can stimulate the Th17 pathway, also
leading to psoriasis [8, 9]. This may also explain
why ustekinumab, which is a IL23 blocker, has a
beneficial effect on this type of psoriatiform
eruption.
Recently, Cabaleiro et al. found an
association between genetic polymorphism
and paradoxal reactions in patients with
psoriasis who were treated with anti-TNF-a
therapies. Five single-nucleotide
polymorphisms were associated [10].
Collamer et al. [11] proposed an algorithm
for the treatment of anti-TNF-a-induced
paradoxical reaction. Depending on the
severity of the paradoxical reaction, patients
should be treated aggressively with topical
corticosteroids, keratolytics and vitamin D
analogs and if necessary additionally with
ultraviolet phototherapy, methotrexate,
acitretin and ciclosporin. For patients who
continue to have recalcitrant skin disease,
biologic therapy with other than TNF
antagonists can be considered. For instance, in
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patients suffering from psoriatic arthritis and
Crohn’s disease, treatment of paradoxical
psoriasis with ustekinumab may be effective
[12].
CONCLUSION
In this case report, we present a patient with a
palmoplantar pustulosis and psoriatic arthritis,
who developed a psoriatiform eruption after
treatment with adalimumab. Different topical
and systemic psoriasis treatments did not have a
beneficial effect on the psoriatic lesions.
Switching to etanercept, another anti-TNF-a
treatment, showed a partial response at first,
but later this patient developed the same
psoriatiform eruption. Treatment with
ustekinumab eventually resulted in an almost
complete remission of the skin lesions and good
control of her psoriatic arthritis.
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